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ABSTRACT 
Background. Previous studies reported that primary aldosteronism (PA) is 
associated with an increased prevalence of anxiety, depression and subnormal 
quality of life (QoL) scores that may be improved after surgical treatment. 
Aim of the Study. The aim of the study was to assess the impact of surgery on 
health-related QoL and depression status of patients suffering from PA, comparing 
the results with a control group of patients undergoing surgery for a non-secreting 
adrenal tumor. 
Materials and Methods. Data on QoL and depression status were prospectively 
collected, from January 2014 to October 2016, before, early after surgery (at 1 
month) and at long term (at least 6 months) in patients with unilateral PA and in a 
control group of patients with non-secreting adrenal tumor submitted to unilateral 
transperitoneal laparoscopic adrenalectomy. QoL was assessed using the Short 
Form 36 (SF-36) Health Survey for Physical (PCS) and Mental Component (MCS); 
the depression status by a 20-item depression scale (DS) questionnaire. 
Results. Twenty-six PA patients and 15 controls were recruited. Biochemical cure 
of the disease was achieved following surgery in all PA patients; hypertension was 
cured in 31% of cases and improved in the remaining 69% of cases. No morbidity 
occurred in both groups. There were no significant differences between PA patients 
and controls concerning demographics, preoperative PCS, MCS and DS values. In 
patients with PA, MCS values improved at early (42.72±13.68 vs 51.56±9.03, 
p=0.0005) and long term  follow up (42.72±13.68 vs 51.81±7.04, p<0.0001); also 
DS values improved at early (15.92±11.98 vs 8.3±8.8, p=0.0002) and long term 
follow up (15.92±11.98 vs 4.57± 6.11, p<0.0001). In PA patients PCS values 
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significantly improved at long term follow up (51.02±8.04 vs 55.85±5.1, p=0.013). 
Also in controls an improvement of MCS and DS scores was found at early and 
long term follow up compared to preoperative values, while no significant 
differences in PCS were found.  
Conclusions. Both PA and non-secreting adrenal tumors affect health-related QoL, 
worsening MCS and DS scores. Adrenalectomy is effective in curing PA, and 
improving MCS and DS scores at early and long-term follow-up, in patients with 
PA and non-secreting adrenal tumors. In PA patient surgery also significantly 
improves PCS at long term follow up. 
 
RIASSUNTO 
Presupposti dello studio. Studi precedenti hanno descritto che l’iperaldosteronismo 
primario (PA) è associato ad un aumento della prevalenza di ansia, depressione e 
peggioramento della qualità di vita (QoL), con miglioramento significativo dopo il 
trattamento chirurgico. 
Scopo dello studio. Lo scopo dello studio è quello di indagare l’impatto della 
chirurgia sulla qualità di vita dei pazienti con PA, comparando i risultati con un 
gruppo di controllo costituito da pazienti sottoposti a surrenectomia per tumori 
surrenalici non secernenti. 
Materiali e Metodi. I dati sulla qualità di vita e lo stato di depressione sono stati 
raccolti prospetticamente, da Gennaio 2014 a Ottobre 2016, preoperatoriamente, 
dopo 1 mese e dopo almeno 6 mesi dall’intervento chirurgico di surrenectomia 
laparoscopica transperitoneale in pazienti con PA lateralizzato e in un gruppo di 
controllo costituito da pazienti con tumori non-secernenti del surrene. La QoL è 
stata valutata utilizzando il questionario SF-36, per valutazione della componente 
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fisica (PCS) e mentale (MCS); lo stato depressivo è stato quantificato utilizzando 
un questionario di valutazione della depressione (DS) costituito da 20 domande. 
Risultati. Sono stati reclutati 26 pazienti con PA e 15 controlli. La cura biochimica 
della malattia è stata ottenuta in tutti i pazienti con PA; l'ipertensione è stata curata 
nel 31% dei casi ed è migliorata nel 69% dei casi. Non si sono verificate 
complicanze chirurgiche in entrambi i gruppi. Non sono state rilevate differenze 
statisticamente significative tra i pazienti con PA e i controlli per quanto riguarda i 
dati demografici e i valori preoperatori di PCS, MCS e DS. Nei pazienti con PA, i 
valori di MCS sono migliorati sia a 1 mese dall’intervento (42.72 ± 13.68 vs 51.56 
± 9.03, p = 0,0005) che a distanza (42,72 ± 13.68 vs 51.81 ± 7.04, p <0,0001). Nei 
pazienti affetti da PA anche i valori di DS sono migliorati sia a breve (15.92 ± 11.98 
vs 8.3 ± 8.8, p = 0,0002) che a lungo termine (15,92 ± 11.98 vs 4.57 ± 6.11, p 
<0,0001); i valori di PCS sono migliorati significativamente solo a distanza 
dall’intervento (51.02 ± 8.04 vs 55.85 ± 5.1, p = 0,013). Anche nel gruppo di 
controllo i valori di MCS e DS sono migliorati sia a breve dopo l’intervento che a 
distanza; in questi pazienti non sono state rilevate variazioni significative nei valori 
di PCS dopo l’intervento. 
Conclusioni. I pazienti affetti da PA e tumori surrenalici non-secernenti sono 
caratterizzati da una QoL peggiore rispetto alla popolazione normale. La 
surrenectomia è efficace nella cura del PA, e nel migliorare i punteggi di MCS e 
DS sia a 1 mese dall’intervento che a lungo termine, sia nei pazienti con PA che nel 
gruppo di controllo. Nei pazienti con PA, i valor di PCS migliorano 
significativamente solo a lungo termine. 
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1.INTRODUCTION
  
1.1 THE ADRENAL GLAND 
The adrenal glands were first described in 1552 by the anatomist Bartolomeo 
Eustachi as ‘‘glandulae renis incumbentes’’ (glands lying on the kidney) (1).  
In 1586, Piccolomineus and Baunin named them the suprarenal glands and nearly 
two-and-a-half centuries later, Cuvier described the anatomical division of each 
gland into the cortex and medulla.  
The adrenal are located in the lateral retroperitoneal area and surrounded by 
perirenal fascia, in close contact with the superior pole of the kidney (2). 
Pararenal fat and perirenal fascia separate the adrenals from the pleural reflection, 
ribs, and the subcostal, sacrospinalis, and latissimus dorsi muscles (2). Posteriorly, 
the glands are near the diaphragmatic crus and arcuate ligament; Laterally, the right 
adrenal resides in front of the 12th rib and the left gland is in front of the 11th and 
12th ribs (2).  
The right adrenal gland is triangular or pyramidal in shape, sometimes called the 
“witch’s hat,” instead the left adrenal gland is semilunar. 
Each adrenal gland weighs approximately 3–6 g and measures roughly 5\2.5\0.5 cm 
(3). 
The adrenal gland combines the outer cortex of mesodermal origin, and the central 
medulla that has a neuroectodermal origin. 
The adrenal cortex has a characteristic bright chrome yellow with a granular surface 
and firm consistency (3,4). The cortex is divided into three zones (4): the zona 
glomerulosa, secretes the mineralocorticoid aldosterone, which regulates salt and 
water homeostasis; the zona fasciculate secretes the glucocorticoid cortisol, which 
regulates carbohydrate metabolism; the zona reticularis secretes sex steroids 
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(estrogen precursors, progesterone, and androgens). The central medulla is dark red 
or pearly gray, depending on the blood content, and is rather friable. It secretes 
catecholamines which modulate the fightor-flight response to stress.  
 
1.2 PRIMARY ALDOSTERONISM 
In 1952, Simpson and Tait isolated aldosterone from the adrenal glands of animals 
and a year later, its structure was described for the first time (5).  
Primary aldosteronism (PA) was first described by Litynski in Poland and Conn in 
the USA (6,7). It is an adrenal disease which causes sodium and water retention, 
potassium excretion, with ensuing hypertension and hypokalemia.  
Aldosterone is the main mineralocorticoid hormone, produced by the zona 
glomerulosa of the adrenal cortex and its production is regulated mainly by 
angiotensin II, resulting from the action of renin secreted by the juxtaglomerular 
apparatus in the kidney on its substrate (angiotensinogen) made by the liver. 
Angiotensin II is the most powerful stimulus for adrenal aldosterone secretion, 
mediated via angiotensin II type 1 receptor (AT1R) in the adrenal cortex (8). In 
addition to circulating angiotensin II, local production of angiotensin II occurs in 
the adrenal gland and contributes to aldosterone release (9). Both 
adrenocorticotropic hormone (ACTH) and potassium also stimulate aldosterone 
secretion.  
Aldosterone binds to the mineralocorticoid receptor in various tissues, inducing 
pleiotropic effects. Its main action is in the kidney, where it increases the expression 
of epithelial sodium channels in the distal tubule, resulting in sodium and water 
reabsorption and potassium secretion. These renal actions contribute to 
extracellular fluid volume expansion, increased blood pressure, decreased serum 
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potassium. The hypokalemia results from aldosterone increasing potassium 
excretion in urine, feces, sweat, and saliva (10). 
Recent guidelines have defined PA as "a group of disorders in which aldosterone 
production is inappropriately high, relatively autonomous from the renin-
angiotensin system, and non-suppressible by sodium loading" (11). The guidelines 
recommend case detection of PA by using the aldosterone-renin ratio measured 
under standard conditions, followed by one of the commonly used confirmatory 
tests (oral sodium loading, saline infusion, fludrocortisone suppression, and 
captopril challenge) (11), although the accuracy of these tests is debated (12). 
PA is the most common cause of endocrine hypertension, and it has been reported 
in more than 11 % of referred hypertensive patients (13-16). 
It is important to search for PA in a systematic way at least in some categories of 
patients, because of its prevalence, and also because patients with PA have higher 
cardiovascular morbidity and mortality than age-, BP- and sex-matched patients 
with essential hypertension (17,18). These categories include patients with Joint 
National Commission stage 2 (>160-179/100-109 mm Hg), stage 3 (>180/110 
mmHg), or drug-resistant hypertension; hypertension and spontaneous or diuretic-
induced hypokalemia; hypertension with adrenal incidentaloma; or hypertension 
and a family history of early-onset hypertension or cerebrovascular accident at a 
young age (<40 years). Case detection is also recommended for all hypertensive 
first-degree relatives of patients with PA (11). 
PA may be caused by unilateral or bilateral adrenal involvement: the unilateral form 
(aldosterone producing adenoma, APA) (Figure 1A) is considered surgical curable; 
for the bilateral adrenal involvement (idiopathic adrenal hyperplasia), which is 
considered non-surgically curable, the medical treatment is indicated. APA and 
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idiopathic adrenal hyperplasia were claimed to account for more than 95% of all 
cases (19). In recent years, several studies have reported novel variants of surgically 
treatable PA, including diffuse or nodular unilateral adrenal hyperplasia (UAH) 
(Figure 1B). It was previously considered to be very rare (0.1%) (19), but is 
actually described to involve from 8% to 70% of cases of surgically treated PA (20-
24). The normalization of aldosterone is the goal of treatment, because chronical 
hyperaldosteronism concurs with high blood pressure in causing cardiovascular 
complications, including, left ventricular hypertrophy, arterial wall stiffening, 
metabolic syndrome, renal damage, myocardial infarction and atrial fibrillation 
(25,26). 
 
 
 Figure 1. Surgical specimens. (A) Aldosterone producing adenoma; (B) 
micronodular diffuse hyperplasia.  
 
1.2.1 Lateralizing techniques 
Only patients with unilateral adrenal hypersecretion may be cured by unilateral 
adrenalectomy, thus the distinction between unilateral and bilateral aldosterone 
hypersecretion is crucial. To this aim adrenal venous sampling (AVS), 
computerized tomography (CT), magnetic resonance imaging (MRI) and 
adrenocortical scintigraphy have been used. 
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AVS was introduced in the late 1960s and became the first test to distinguish 
unilateral from bilateral primary aldosteronism (27). Adrenocortical scintigraphy, 
CT and MRI developed later and they are the primary procedures used to 
differentiate unilateral from bilateral adrenal abnormalities, because they are less 
invasive than AVS. 
 
Image-based techniques. CT is the most widely used imaging test; MRI performs 
in a similar way (28) (Figure 2). Most aldosterone-producing adenomas are less 
than 20 mm in diameter (29,30). The finding of a small adrenal nodule in patients 
with PA suggests the presence of an APA; however, it does not exclude the 
coexistence of a non-secreting adenoma and idiopathic PA (11,31).  
 
Figure 2. Computed tomography. (A) Right aldosterone producing adenoma 
(arrow); (B) bilateral adrenal hyperplasia (arrow). 
 
A recent meta-analysis (14) demonstrated that the proportion of patients with an 
unilateral nodule on CT or MRI imaging, and a bilateral or contralateral secretion 
documented by AVS, was about 20%. 
Since the prevalence of non-secreting adenoma increase with age, their presence is 
less likely in young patients with PA. 
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Thus, the presence of an isolated characteristic adrenal adenoma > 1 cm in PA 
patients aged less than 40 is considered by some experts as a surrogate for 
diagnosing unilateral aldosterone hypersecretion (16,21), although results from 
recent series do not support use of this strategy (32). 
The guidelines recommend the use of CT in all patients with confirmed PA to detect 
an adrenal carcinoma, even if surgery is not otherwise considered (11). However, 
adrenal carcinomas presenting as isolated PA are rare, 2.5% of patients with 
adrenocortical carcinoma, which represents 0.05-0.2 % of all malignancies (33).  
Moreover, CT and MRI results were found to disagree with AVS in a considerable 
proportion of patients. CT/MRI would show a unilateral abnormal adrenal gland 
and AVS would describe a contralateral or bilateral aldosterone hypersecretion, or 
image-based techniques would show bilateral normal or abnormal adrenal glands 
when aldosterone hypersecretion is lateralized in only one gland (34,35-38).  
A prospective study of 203 patients (21) showed that operative planning based on 
anatomical imaging alone would have inappropriately excluded 21.7% of patients 
from adrenalectomy and would have led to unnecessary surgery in 24.7%; this 
situation led to a “renaissance” of AVS. 
 
Adrenal vein sampling. AVS involves the measurement of aldosterone and 
cortisol levels in the infra-adrenal inferior vena cava and in the adrenal veins of 
both sides (Figure 3). Considering the variability of aldosterone secretion, some 
experts advocate AVS during exogenous ACTH infusion to maximize cortisol 
secretion, enhancing the assessment of selectivity of catheterization and to 
maximize differences of aldosterone between sides (21). Other experts suggest 
AVS in the early morning, when peaks ACTH secretion (11). While comparative 
study reported that exogenous ACTH infusion does not improve the detection of 
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unilateral aldosterone hypersecretion if the two adrenal veins are catheterized 
simultaneously (39), most experts agree that ACTH does facilitate the assessment 
of selectivity, but may confound the ascertainment of lateralization.  
There is not agreement regarding the definition of successful selectivity and 
lateralization in AVS (11). Catheter insertion is considered successful under 
unstimulated conditions, if cortisol concentrations are 1.1 to 3 times higher in the 
adrenal veins than in the inferior vena cava or in a peripheral vein. Aldosterone 
concentrations in both adrenal veins are then divided by the corresponding cortisol 
concentrations. Aldosterone secretion is considered to be lateralized if the 
aldosterone to cortisol ratio is 2 to 5 times higher on the dominant side than contra-
laterally.  
AVS has a rate of failure between 3 (40) and 22% (34). It is an invasive procedure 
but it carries a very tiny risk of complications, when performed by skilled 
radiologist (41,42). The only clinically relevant complication is the adrenal veins 
rupture (0.6%), usually managed with conservative treatment (41). 
 
 
Figure 3. Adrenal venous sampling (angiographic images). (A) Identification of 
left adrenal vein; (B) simultaneous catheterization of both adrenal veins. 
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The objective of surgery is to resolve the aldosterone hypersecretion, and not just 
to remove a nodule. Since aldosterone hypersecretion can occur even with no 
adrenal enlargement (as detected by CT and MRI), AVS was found to be superior 
to image-based techniques for surgical decisions, as unilateral hypersecretion may 
be associated with UAH that can be undetectable on imaging (21,29,34). 
Recently, some authors tried to develop a score to avoid the use of AVS. Kupers et 
al published data on a clinical prediction score (CPS), developed to diagnose 
unilateral PA, using a combination of biochemical and radiological characteristics 
(43). Applying this score, 30% of the cohort of patients they reported could 
potentially have avoided AVS and proceeded directly to surgery. Likewise, a 
prospective study by Sze et al. (44), suggested that the CPS has the potential to lead 
to occasional erroneous patient selection for adrenalectomy; therefore, it may be 
useful for clinical decisions only in cases of unsuccessful AVS or in centers where 
AVS is not available. 
 
Iodocholesterol scintigraphy. [131I]19-Iodocholesterol scintigraphy was first 
used in the early 1970s (45). In 1977, the NP-59 scan [6-131I]iodomethyl-19-
norcholesterol (NP-59) performed with dexamethasone suppression was introduced 
and had the advantage of correlating anatomical abnormalities with function (46). 
However, its sensitivity depends heavily on the size and the degree of hyperfunction 
of the adenoma (47,48). The introduction of the multiple head gamma camera and 
SPECT technique improved imaging resolution and enhanced the ability of NP-59 
scintigraphy to detect smaller adrenal lesions (49). 
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However, this technique is often not helpful in interpreting micronodular findings 
obtained with high-resolution CT, because of a poor tracer uptake in adenomas 
smaller than 1.5 cm in diameter (50).  
In 2014 Lu et al evaluated the ability of NP-59 scintigraphy to predict outcome in 
PA after adrenalectomy; they concluded that semiquantification of NP-59 
scintigraphy shows ability similar to AVS in differentiating APA from bilateral 
idiopathic adrenal hyperplasia and has excellent ability to predict postsurgical 
outcomes of adrenalectomy (51).  
However, other series have found misleading results in establishing lateralization 
with NP-59 (32). Moreover, NP-59 is an expensive and time-consuming procedure 
and its use is limited by the poor availability of the radiotracer (52). 
 
Thus, most experts now agree that the referral diagnostic test for lateralization of 
aldosterone hypersecretion is AVS, because the interpretation of other imaging 
techniques (CT, MRI, adrenocortical scintigraphy) may lead to inappropriate 
treatment of PA patients (11,14,20,21). 
 
1.2.2 Medical treatment vs surgery 
Adrenalectomy represents the elective treatment in APA and other unilateral PA 
variants, while the administration of mineralcorticoid receptor antagonists (MRAs) 
is the choice for patients with bilateral disease and non-surgically correctable PA. 
The two main MRAs currently available are spironolactone and eplerenone (53) 
and the guidelines recommend the first as the primary agent for the management of 
PA, and eplerenone as an alternative (11). 
MRAs or potassium chloride are commonly prescribed also to hypokalemic patients 
with APAs to correct hypokalemia before surgery, in order to avoid the risk of 
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hypokalemia-related arrhythmia during anesthesia (54). After surgery, the 
incidence of hypoaldosteronism or hyperkalemia is not increased by the 
preoperative treatment (55). 
Some studies that compared spironolactone to surgery also in patients with APA 
reported no differences between treatments for the control of either BP or serum 
potassium concentrations (56).  
Few follow-up echocardiographic studies have been conducted in PA patients 
treated with either adrenalectomy or MRAs. Whereas adrenalectomy was almost 
consistently found to rapidly decrease left ventricular mass (LVM), the effects of 
MRAs were more controversial (57-60). According to a recent meta-analysis, no 
significant difference in LVM change between patients with PA who underwent to 
adrenalectomy or treatment with MRAs were found, despite a greater effect of 
surgery over medical treatment in reducing blood pressure (61). 
However, spironolactone has adverse effects such as gynaecomastia, mastodynia, 
menstrual abnormalities and erectile disfunction (62); otherwise the newest 
eplerenone is more expensive and seems to be less effective but better tolerated 
(63). 
According to some authors, it remains uncertain whether adrenalectomy for 
lateralized disease, should routinely be offered to PA patients (64).  
Reimel et al. attempted to compare the cost-effectiveness of a guideline-based 
surgical strategy with universal pharmacologic management, using a Markov state 
transition model (65). They demonstrated that screening for PA and resecting an 
APA was the least costly strategy. Even though most APA patients can be managed 
medically, in order to make universal pharmacologic therapy the less costly strategy 
for patients with an approximately 40-year life expectancy, the probability of 
finding a unilateral APA should be less than 10%; the cost of adrenalectomy should 
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be more than double; the cost of AVS should be more than four-fold higher than 
current and the surgical failure rate should be more than sextuple.  
 
1.2.3 Surgical procedures in primary aldosteronism 
The first adrenalectomy for PA was performed in December of 1954, just two 
months after the description of its metabolic basis. A middle aged hypertensive 
female underwent adrenalectomy for a 4-cm unilateral adrenal adenoma, curing her 
symptoms. 
Open vs laparoscopic adrenalectomy. Open removal of the aldosterone secreting 
tumours, by either the transabdominal or the lumbar approach, was unchallenged 
until 1992, when Gagner, Suzuki and Higashihara were published and opened the 
option for laparoscopic excision, performed via a transperitoneal approach (66-68). 
The supine anterior approach was described in 1995 (69), whilst other authors have 
described the retroperitoneoscopic approach (70,71). 
Laparoscopic adrenalectomy, has been proven to be a safe and effective treatment 
for PA (72); laparoscopically treated patients have fewer postoperative 
complications and are equally likely to improve in blood pressure and correct 
hypokalemia, if present preoperatively, when compared with patients treated with 
open adrenalectomy. Additional benefits of laparoscopy are smaller incisions, 
decreased postoperative pain, and shorter hospital stay (73,74). In a recent review, 
laparoscopic adrenalectomy showed a morbidity of 5-14%, a mortality below 1%, 
and a mean hospital stay around 3 days (75). Complications of laparoscopic 
adrenalectomy may include conversion to open surgery, hematoma due to 
intraoperative vascular injury, thromboembolism, pneumothorax or hemothorax. 
Transperitoneal vs retroperitoneal approach. Laparoscopic surgery using the 
transperitoneal or retroperitoneal approaches is currently the preferred strategy to 
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treat patients with unilateral PA (76,77) (Figure 4). In general, three recent meta-
analyses compared the transperitoneal and retroperitoneal adrenalectomy: two 
concluded that the two techniques have equivalent outcomes (78,79) whereas the 
other claimed the retroperitoneal approach to be superior in short-term outcomes 
(80). 
 
Figure 4. Position of patients for left transperitoneal laparoscopic adrenalectomy. 
 
Total vs partial “sparing”adrenalectomy. For a long time, unilateral total adrenal 
excision has been considered the technique of choice in patients with surgically 
correctable PA. However, the routine unilateral partial adrenalectomy in order to 
preserve the remnant adrenal function and avoid potential adrenal insufficiency has 
also been advocated (81).  
This strategy may expose to increased risk of failures because of incomplete 
excision with subsequent persistent and recurrent PA, thus the risk-to-benefit ratio 
of partial adrenalectomy must be weighed. Partial adrenalectomy in cases of 
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unsuspected UAH may theoretically achieve an incomplete removal of abnormal 
adrenal tissue.  
In fact, Shigematsu et al found that aldosterone hypersecretionis not localized 
exclusively in the adenoma cells but also in the adjacent hyperplastic or 
micronodular tissue (82). However, little is known about how the cells expressing 
the enzyme for aldosterone synthase are distributed in the adrenal glands; new 
findings in immunohistochemistry and immunofluorescence may provide useful 
tools for diagnosis and treatment of adrenocortical adenomas (83,84). 
 
When an unilateral disease has been unequivocally established adrenalectomy 
results in the normalization of aldosterone secretion in close to 100% of the cases. 
It also achieved the correction of hypokalemia, if present before surgery, in virtually 
all patients (32). Furthermore, the cure of hypertension is reported in about 30-60% 
of cases, and in the remaining patients a marked improvement of BP values is 
described (58,75). 
The wide variation of BP outcome after adrenalectomy could be explained by the 
different criteria used to define cure and improvement, and even more by the fact 
that BP is a highly complex phenotype, deriving from several factors. For example 
a patients with no cure of PA after adrenalectomy can became normotensive just 
for lifestyle measures and/or because of myocardial infarction. Conversely a 
patients with concomitant essential hypertension is unlikely to be cured even if the 
PA is fully corrected. Hence, we strongly advocate the need of considering the 
postoperative normalization of ARR as the main endpoint for determining 
outcomes of PA. 
Several authors have suggested potential predictors of a postoperative hypertension 
cure in PA patients, including female sex, young age, no family history of 
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hypertension, short duration of hypertension, low preoperative BP, few prescribed 
antihypertensive drug classes, low body mass index, and high estimated glomerular 
filtration rate (29,75,85-88). 
Zarnegar et al developed the Aldosteronoma Resolution Score, which was 
composed of 4 predictors (number of antihypertensive drugs, body mass index, 
duration of hypertension, sex) and roughly estimated postoperative hypertension 
cure according to 3 categories of likelihood (87). 
Utsumi et al have recently proposed a more accurate nomogram that could predict 
hypertension cure in PA patients after laparoscopic adrenalectomy. Age, sex 
duration of hypertension, and number of antihypertensive drug classes are included 
in the nomogram (88). These score can help clinicians to calculate the probability 
of postoperative hypertension cure in PA patients and inform patients 
preoperatively. 
 
1.2.4 Primary aldosteronism and quality of life 
Besides leading to increased cardiovascular morbidity and mortality (26), PA has 
been claimed to be associated to higher prevalence of anxiety and depression, with 
potential impact on health-related quality of life (QoL), through mechanisms and 
pathways that remain to be clarified (89,90). Undoubtedly, both surgical and 
medical treatment of PA can control hypertension and severe cardiovascular 
damages in the long term (58). However, whether these two strategies, which show 
substantial differences (as surgery eliminates the source of aldosterone excess while 
mineralocorticoid receptor antagonists simply control it) have the same beneficial 
effects on QoL and depression remains uncertain (91,92). 
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Measurement of QoL investigates the functional status of the individual and the 
patient’s appraisal of health, allowing assessment of the impact of a disease and/or 
treatment from the patient’s perspective. 
Therefore, health-related QoL has been investigated in patients suffering from PA 
by few studies that have reported subnormal scores compared to normal population 
(93,94); amelioration of health-related QoL as well as scores for depression and 
anxiety in patients with PA after surgery with respect to medical treatment has been 
reported (92,95).  
However, in some studies, it could not be excluded that non-specific psychological 
effects secondary to surgery could be at least partly responsible for some 
improvement in QoL (91).  
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2. AIM OF THE STUDY 
The aim of the present study was to assess the impact of surgery on health-related 
QoL (both in Mental and Physical components) and depression status of patients 
suffering from PA.   
The purpose was to compare the results of PA patients with the best possible 
controls, to underline the role of hyperaldosteronism. Thus, patients with non-
secreting adrenal tumor who underwent to the same intervention (laparoscopic 
transperitoneal adrenalectomy), but without hormone excess, were selected.  
 
3. PATIENTS, MATERIAL AND METHODS 
Data were prospectively collected from January 2014 to October 2016 at Minimally 
Invasive Endocrine Surgery Unit of Padua University. The study included patients 
with unilateral PA and a control group of patients with non-secreting adrenal tumor 
submitted to laparoscopic transperitoneal adrenalectomy by flank approach, 
performed by the same surgeon (M.I.). The institutional ethics committee approved 
the study and informed consent was obtained from all patients. 
PA was diagnosed based on a plasma aldosterone concentration greater than 15 
ng/dL and an aldosterone/renin ratio greater than 40 ng/dL:ng/mL/h, measured after 
washout of interfering drugs or after changes of the drug treatment as previously 
detailed (32). The diagnosis was confirmed by saline infusion and/or the captopril 
test (32). 
Surgery was performed in patients with lateralized PA, according to the results of 
preoperative lateralizing techniques. Lateralizing techniques included CT scan 
and/or MRI and selective AVS. 
AVS was performed with bilateral simultaneous catheterization, by using one 
catheter for each adrenal vein. Successful selective catheterization was usually 
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confirmed when the ratio between cortisol concentration in each adrenal vein and 
the inferior vena cava was greater than 1.1; unilateral aldosterone hypersecretion 
was usually confirmed when the ratio of adrenal vein aldosterone concentration to 
the homolateral cortisol concentration on the side with the higher ratio over the 
contralateral aldosterone to cortisol ratio (AVS ratio) was greater than 2. 
The control group was composed of patients suffering from non-secreting adrenal 
tumor, defined as an asymptomatic adrenal mass, incidentally detected on imaging 
not performed for suspected adrenal disease, in patients without glucocorticoid, 
catecholamine or mineralcorticoid hypersecretion (assessed by plasmatic ACTH, 
24-hour urinary free cortisol levels and 1 mg overnight dexamethasone suppression 
test, 24-hour urinary catecholamine or metanephrine levels and plasma renin and 
aldosterone levels, respectively).  
In these patients, surgery was indicated by the presence of adrenal mass with 
suspicious radiological findings (even without evidence of local invasion or distant 
metastases), evidence of significant tumor growth during follow-up imaging and/or 
patient preference. Patients with adrenal or extra-adrenal malignancies or any 
psychiatric disorders were not included in the study. 
The surgical procedure was performed with the patient in lateral decubitus flank 
position. Pneumoperitoneum (at 12-14 mmHg by CO2) is usually made by Hasson 
cannula inserted by open technique. A subcostal port is placed for the laparoscope, 
and two/three other 5/10 mm ports sited. For right adrenalectomy the liver is 
mobilized and retracted and the right medium adrenal vein is identified by 
following the lateral edge of the vena cava. The main right adrenal vein is identified 
and divided early. Then the adrenal branches from the inferior phrenic artery, aorta, 
and the renal artery are divided.  
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On the left side the colonic flexure is mobilized and the splenorenal ligament 
dissected, allowing the fall of the spleen medially and the identification of the tail 
of the pancreas and the splenic vein and artery. The avascular plane separating 
adrenal gland from the tail of the pancreas and the splenic vein is opened, allowing 
the view of the inferior adrenal vein, going into the left renal vein. The inferior 
adrenal vein is divided and then the gland is dissected and removed. Small arterial 
vessel from superior, medium and inferior pedicle can be easily coagulated. In all 
cases, the adrenal gland is removed via a retrieval bag. 
The biochemical cure of PA was defined by the normalization of aldosterone/renin 
ratio (<40 ng/dL:ng/mL/h) and serum potassium levels (≥3.5 mmol/L).  
Patients were defined being hypokalemic if their serum potassium level was less 
than 3.5 mmol/L or if they needed potassium supplementation to maintain 
normokalemia. Hypokalemia was considered cured if serum potassium levels 
regained the normal range without potassium supplementation. 
Arterial hypertension was defined by a systolic BP of 140 mm Hg or greater, 
diastolic BP of 90 mm Hg or greater, or both and/or the presence of antihypertensive 
medical treatment. Hypertension was considered cured if BP regained normal levels 
after discontinuing any medical treatment; it was considered improved when the 
hypertensive patients switched from a higher to a lower hypertension degree or the 
antihypertensive drugs were reduced. 
Health-related QoL and depression status, were assessed preoperatively (at the time 
of hospital admission) and postoperatively at 1-month outpatient control and at long 
term, at least 6 months after surgery. 
QoL was evaluated using the Italian version of Short Form 36 (SF-36) Health 
Survey for a Physical (PCS) and a Mental Component (MCS). The SF-36 is a 36 
item self-administered questionnaire measuring QoL across eight domain obtaining 
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eight scaled scores, which are the weighted sums of the questions in their section. 
These domains are physical functioning, social functioning, role limitations due to 
physical problems, role limitations due to emotional problems, vitality, bodily pain, 
general health perceptions, and general mental health. PCS and MCS are a summary 
of physical and emotional QoL respectively. Scores may range from 0 (poorest 
health status) to 100 (best health status). The depression status was evaluated using 
a 20-item depression scale (DS) questionnaire; the score may range from 0 (best 
status) to 60 (poorest status) (26). 
Results were compared with published normative values for the Italian population 
(96). 
Records of the patients were reviewed to gather relevant demographics, body mass 
index (BMI, defined as body weight (kg)/height (m2), normal values 20 to 24.9), 
hormonal parameters (including glucocorticoid, mineralcorticoid and catecolamine 
assays), BP values, number of antihypertensive drugs, side and size of adrenal 
masses, intra and postoperative morbidity and definitive pathology. 
Postoperative follow-up data (including hormonal, BP parameters, number of 
antihypertensive drugs), were assessed 1 month after surgery and at long-term. 
Results were expressed as absolute numbers, ratio, percentage, mean (± standard 
deviation) or median (range).  
Statistical analysis was performed using Fisher’s exact test for categorical 
variables, Student’s paired t test, Wilcoxon matched-paired test, Mann–Whitney U 
test, as appropriate. P <.05 was considered statistically significant. 
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4. RESULTS 
Twenty-six PA patients and 15 patients with non-secreting adrenal tumor who also 
underwent laparoscopic transperitoneal adrenalectomy were recruited. 
No significant differences were found between PA patients and controls concerning 
demographics, BMI, side and dimension at preoperative imaging of the mass 
(Table 1). 
 
Table 1. Demographics, and general features in patients with Primary 
Aldosteronism and Controls (patients with non-secreting adrenal tumor) 
undergoing laparoscopic adrenalectomy. 
 PA PATIENTS 
(n=26) 
CONTROLS 
(n=15) 
p value 
Sex (female/male) 10/16 6/9 0.92 
Age (years) 54±11 56±9 0.54 
Body Mass Index 
(kg/m2) 
26.6±4 27.4±6 0.95 
Side of the mass 
(left/right) 
12/14 9/6 0.59 
Size of the mass (mm) 
median(range) 
15 (6-30) 44 (25-60) <0.0001 
PA: Primary aldosteronism 
 
The size of the adrenal mass at preoperative imaging was significantly higher in 
controls than in PA patients (p<0.0001) (Table 1). 
Hypertension was present in all patients with PA and in five patients with non-
secreting adrenal tumor (p<0.0001); hence, the mean systolic and diastolic BP were 
significantly higher in PA patients than in controls (154±19 vs 125±9 mmHg, 
p<0.0001 and 91±12 vs 75±8 mmHg, p=0.0002, respectively); likewise, the number 
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of antihypertensive drugs was significantly higher in PA patients than in controls 
(3.42±1.47 vs 0.60±0.99, p<0.0001).  
Preoperative MCS and DS scores were impaired in PA patients compared to normal 
Italian reference population; similar finding were found also in the control patients. 
No significant differences were found between PA patients and controls concerning 
preoperative PCS (51.02±8.04 vs 51.16±9.63, p=0.75), MCS (42.72±13.68 vs 
39.39±12.81, p=0.39), and DS values (15.92±11.98 vs16.26±12.56, p=0.91). 
All patients underwent uneventful laparoscopic surgery; no conversion to open 
approach was performed, no blood transfusion was required and no intra- or post-
operative morbidity occurred in both groups.  
Pathological specimens revealed benign adrenal tumors in all cases in both groups. 
One month after surgery  
PA was biochemically cured in all patients, according to the normalization of the 
aldosterone/renin ratio and serum potassium levels; hypertension was cured in 10 
cases (38%), and improved in the remaining 16 cases (62%). The systolic and 
diastolic BP were significantly reduced (from 154±19 to 130 ± 15 mmHg, p<0.0001 
and from 91±12 to 78±9 mmHg, p<0.0001); also the mean number of 
antihypertensive drugs was significantly reduced (from 3.42±1.47 to 1.15±1.1, 
p<0,0001).  
In patients with PA, MCS values significantly improved (42.72±13.68 vs 
51.56±9.03, p=0.0005) (Figure 5), mainly due to an amelioration in the “mental 
health” (42.7±15.7 vs 53.17±7.33, p=0.001) and “emotional role” (45.5±11.83 vs 
51.23±9.84, p=0.001) scores. Also DS values significantly improved (15.92±11.98 
vs 8.3±8.8, p=0.0002). Conversely, no quite significant differences were found 
regarding PCS scores (51.02±8.04 vs 48.01±6.85, p=0.07) (Figure 5). 
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In controls, no significant changes in BP levels and number of antihypertensive 
drugs was found; also in the five hypertensive patients no changes in BP values and 
number of antihypertensive drugs were detected after adrenalectomy. 
Also in controls MCS (39.39±12.81 vs 50.62±8.68, p=0.0005) and DS 
(16.26±12.56 vs 7.86±7.19, p=0.001) values improved after surgery, mainly due to 
a significant amelioration in the “mental health” (46.69±12.01 vs 53.79±6.36, 
p=0.006) and “emotional role” (33.19±13.69 vs 46.93±9.26, p=0.001) scores 
(Figure 5). No significant differences were found regarding PCS values 
(51.16±9.63 vs 48.60±6.99 p=0.26). 
No significant differences were found between PA and control patients concerning 
postoperative MCS and PCS and DS (p= 0.69, p=0.81 and p= 0.93, respectively). 
Long-term follow-up 
The median time of follow-up was 231 days (range 184-391) for PA patients and 
270 days (range 211-369) for controls. 
At long term, all patients that underwent surgery for PA were still biochemically 
cured, but two patients that at one month had achieved the cure of hypertension, 
restarted antihypertensive therapy; thus, the hypertension cure was achieved in 8 
patients (31%). 
At long term follow up PA patients had systolic and diastolic BP values 
significantly reduced (from 154±19 to 129± 13 mmHg, p<0.0001 and from 91±12 
to 79±8 mmHg, p<0.0001), compared with preoperative values; also the mean 
number of antihypertensive drugs was significantly reduced (from 3.42±1.47 to 
1.28±1.2, p<0,0001).  
These patients had no significant differences in BP values and number of 
antihypertensive drugs one month after surgery and at long term follow up. 
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In patients with PA, a significant improvement in PCS (51.02±8.04 vs 55.85±5.1, 
p=0.013), MCS (42.72±13.68 vs 51.81±7.04, p<0.0001) and DS (15.92±11.98 vs 
4.57± 6.11, p<0.0001) values was described at long term, compared with 
preoperative period; at long term PCS values improved significantly, compared 
with values recorded one month after surgery (p=0.0002) (Figure 5). 
At long term, also in controls MCS (39.39±12.81 vs 49.30±10.46, p=0.001) and DS 
(16.26±12.56 vs 6.80±5.64, p=0.002) values improved after surgery, mainly due to 
a significant amelioration in the “mental health” (46.69±12.01 vs 54.64±7.87, 
p=0.007) and “emotional role” (33.19±13.69 vs 51.62±9.87, p<0.0001) scores 
(Figure 5). No significant differences were found regarding PCS values 
(51.16±9.63 vs 53.91±4.30 p=0.25). However, compared with values recorded one 
month after surgery, at long term PCS values improved significantly (p=0.04). 
Also at long term, no significant differences were found between PA and control 
patients concerning MCS and PCS and DS (p= 0.58, p=0.16 and p= 0.18, 
respectively). 
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Figure 5. PCS, MCS and DS values in PA patients and controls, preoperatively,  
1 month after surgery and at long term. PA: primary aldosteronism; PCS: Physical 
Component Score; MCS: Mental Component Score; DS: depression scale. 
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5. DISCUSSION 
PA is a common, albeit often overlooked, cause of hypertension which is often 
severe and/or drug resistant and, therefore, associated with cardiovascular damage 
and a worse prognosis (17,97). Moreover, it implies clear cut alterations of the 
renin-angiotensin-aldosterone system, which suggests that it entails multiple 
reasons to imply a worsened QoL, given that the derangements of this important 
system can affect QoL (89,90). 
Hypertension is an important factor for reduced QoL: an impairment of QoL has 
been reported in patients with essential hypertension compared to normal controls 
in the somatization and psychological distress (98). 
Along with this hypothesis, health-related QoL in patients suffering from PA has 
been previously investigated only by 3 studies (93,94,99). 
In 2010, Sukor et al (99) examined health-related QoL in 22 patients with unilateral 
PA before and after unilateral adrenalectomy at 3 and 6 months, using SF-36 
questionnaire. They found a significant improvement in the QoL of these patients 
both in physical and mental component. However, they did not examine depression 
and anxiety. 
In 2011 the same authors (93) compared the results of the previous study with those 
from 21 patients with bilateral PA, before or after commencing medical treatment, 
and with those of the normal Australian population. They confirmed that PA 
patients had subnormal QoL scores compared to normal population. Moreover, they 
described that QoL improved in all patients with bilateral PA undergoing medical 
treatment, but more slowly and to a lesser degree than in patients undergoing 
surgery for unilateral PA. 
In 2012, Kunzel et al (94) published the results of a cross sectional study data from 
the German Conn Registry examining health-related QoL using SF12 
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questionnaire, in which they investigated acute impairment of QoL and long-term 
treatment effects in patients with PA. The study included 132 patients with PA, 
stratified according to the treatment status: 27 newly diagnosed, untreated; 52 in 
chronic medical treatment, 49 patients treated with adrenalectomy. The study 
confirmed that PA patients had a worse physical and mental condition than the 
normal German reference population; untreated and medically treated patients 
reported the lowest scores.  
Our study differed substantially from these previous studies, in that we used the 
best possible controls, i.e. patients with a non-functioning adrenal mass treated with 
adrenalectomy. 
This allowed adjustment for the potentially confounding effect of being harboring 
an adrenal tumor and of being submitted to adrenalectomy. Moreover, our study 
was aimed to clarify the impact of surgery on health-related QoL (both in Mental 
and Physical components) and for the first time on depression status, in patients 
suffering from PA. 
In agreement with previous studies, we confirmed that patients with PA have an 
impaired QoL and depression status compared with normal population, as assessed 
by worse MCS and DS scores.  
In PA patients, MCS (especially in the mental health and emotional role 
dimensions) and DS values significantly improved 1 month after surgery and at 
long term follow-up, confirming the beneficial effect of adrenalectomy previously 
reported (93). However, we failed to find significant differences with the controls, 
since also these patients (without aldosterone excess) showed an impaired 
preoperative MCS and DS scores, and a significant amelioration one month and at 
long term after surgery. Interestingly, also in controls MCS improvement was 
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mainly due to mental health and emotional role amelioration. However, the 
amelioration was more evident in PA patients. 
Even if controls and PA patients were similar according to demographics and type 
of surgical procedure, the former had lower BP levels, larger adrenal masses and 
underwent surgery mainly because of a suspicion of malignancy, while there was 
not suspicion for the latter. 
Thus, it remains unclear if it may be related to the reduction of BP levels or 
antihypertensive drug treatment (with a possible reduction of drug-related size 
effects), to the aldosterone/renin system normalization or a non-specific 
psychological effect of surgery.  
We may argue that in control population the thought of impending surgery and the 
uncertain nature of the non-secreting adrenal mass might have affected the mental 
component and increased the depression status before surgery. Obviously, both 
factors might have been solved after surgery, since in all cases definitive pathology 
described a benign adrenal tumor; however other psychologic effects of 
adrenalectomy may not be excluded, as previously reported (91). 
In the present study, no significant amelioration of PCS scores was detected in PA 
patients one month after surgery; this finding might be related to the sequelae of 
recent surgery. In fact, in PA patients the improvement in PCS values become 
evident at long term follow-up. This is in agreement with previous studies that 
demonstrated at 3 months a significant increase of physical condition, after disease 
cure and BP normalization or amelioration [99]. In the control group no significant 
variations were detected in PCS values at one month and at long term, compared 
with preoperative values. However, some limitations to the present study that might 
have biased the results should be underlined; the mental component of health–
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related QoL is difficult to explore; moreover, the SF-36 and DS questionnaires are 
not disease specific. 
Furthermore, the administration of the baseline questionnaire during hospitalization 
for surgery, when factors such as optimism or anxiety and fear of surgery could 
have some effects, might have affected the results in terms of worsening QoL and 
depression as compared to the normal population. However, if any, the effect was 
likely similar in both PA and controls.  
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6. CONCLUSIONS 
PA affects the health-related QoL, worsening the mental component and the 
depression status. Adrenalectomy is effective in curing PA, and improves the 
mental component of health-related QoL and depression status at 1 month and at 
long term. At long term, surgery determines an improvement also in the physical 
component of health-related QoL of PA patients. 
The role of hormonal cure of PA and the possible weight of the psychological 
effects of surgery itself in affecting QoL need to be further explored, since some 
relevant results may be observed also in patients undergoing surgery for non-
secreting adrenal masses. Further studies are needed to confirm these results at a 
longer follow up and with a larger population. 
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